US Could Save Nearly $1 Billion With Pembrolizumab Dosing Change

This video examines how a change to weight-based pembrolizumab dosing in first-line PD-L1 –positive lung cancer could save nearly $1 billion in US healthcare costs.

Source: CancerNetwork - June 13, 2017 Category: Cancer & Oncology Authors: Daniel A. Goldstein, MD Tags: Conferences/ASCO Street Team News Practice & Policy Videos Lung Cancer Source Type: news